The DOI matches its Crossref record.
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients
Open accessAbstract
Despite advances in anticancer treatment, lung cancer still has poor prognosis. Recently, a cancer stem cell (CSC) hypothesis has emerged describing a small subset of tumor cells with stem cell properties. CSCs found in many solid tumors express CD133 antigen on the cell surface. The presence of CSC is correlated with poor survival of patients with glioblastomas, colon or prostate cancers. In this study, we evaluated whether CD133 expression in non‐small cell lung cancer (NSCLC) has a prognostic value in patients' survival. We also analyzed whether CD133 positivity of NSCLC correlates with the expression of resistance‐related proteins, angiogenic factors, oncogenes, proliferative activity or apoptosis. CD133 expression was retrospectively examined in a total of 88 cases of previously untreated NSCLC by immunohistochemistry. We found no correlation between CD133 positivity or the amount of CD133+ cells with NSCLC patients' survival, expression of oncogenes c‐myc, c‐N‐ras, c‐jun, c‐fos, c‐erbB1, c‐erbB2 or p53, angiogenic factors VEGF, VEGFR‐1, FGF, FGFR‐1, tissue factor and with proliferative activity or apoptosis in NSCLC tissues. However, there was a significant association between the expression of resistance‐related proteins glutathione S‐transferase, thymidylate synthase, catalase, O 6‐methylguanine‐DNA methyltransferase and p170 and CD133. Because CD133 expression is linked to a resistant phenotype, detection of CD133+ cells may be useful to predict efficacy of cytotoxic therapy but CD133 is not a strong prognostic parameter for survival of patients with NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sullivan, J. P., Spinola, M., Dodge, M., Raso, M. G., Behrens, C., Gao, B., Schuster, K., Shao, C., Larsen, J. E., Sullivan, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0881 · Cited by 416
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
Stem Cells and Cell Therapies in Lung Biology and Lung Diseases
Weiss, D. J., Kolls, J. K., Ortiz, L. A., Panoskaltsis-Mortari, A., & Prockop, D. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200804-037dw · Cited by 309
Grosse‐Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D., & Kunz‐Schughart, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4086 · Cited by 301
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
Wang, X., Yin, H., Zhang, H., Hu, J., Lu, H., Li, C., Cao, M., Yan, S., & Cai, L. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0447-7 · Cited by 31
Metadata
- Authors
- Salnikov, A. V., Gladkich, J., Moldenhauer, G., Volm, M., Mattern, J., & Herr, I.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-11-04
- Volume
- 126
- Issue
- 4
- Pages
- 950-958
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2045476312
- Cited by
- 163
- References
- 0
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients. https://app.cochat.ai/papers/10.1002/ijc.24822
- The paper
- Salnikov, A. V., Gladkich, J., Moldenhauer, G., Volm, M., Mattern, J., & Herr, I. (2010). CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients. International Journal of Cancer. https://doi.org/10.1002/ijc.24822
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.